阿替普酶治疗急性肺栓塞的研究进展  

Research Progress of Alteplase in the Treatment of Acute Pulmonary Embolism

作　　者：曹勤 陆佳赟 谈继玉 古丽萍 瞿发林 CAO Qin;LU Jiayun;TAN Jiyu;GU Liping;QU Falin(Department of Pharmacy,No.904 Hospital of the Joint Logistics Support Force,Wuxi 214044,China)

机构地区：[1]联勤保障部队第九〇四医院药剂科,江苏省无锡市214044

出　　处：《实用心脑肺血管病杂志》2021年第6期7-11,共5页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

摘　　要：阿替普酶是一种高选择性纤维蛋白酶原激活剂,该药可改善急性缺血性脑卒中和急性心肌梗死患者的预后及生活质量。近年来,阿替普酶治疗急性肺栓塞的研究逐渐增多,本文重点介绍了其在治疗急性肺栓塞中的临床应用、使用剂量、与其他溶栓药疗效的比较及联合用药情况,分析表明阿替普酶溶栓作用强、出血不良反应少,是目前临床推荐的治疗急性肺栓塞的主要溶栓药。Alteplase is a highly selective plasminogen activator,it can improve the prognosis and quality of life of patients with acute ischemic stroke and acute myocardial infarction.In recent years,studies on alteplase in the treatment of acute pulmonary embolism is gradually increasing.The article focuses on its clinical application in the treatment of acute pulmonary embolism,the dosage,the comparison with other thrombolytic drugs,and the combined use of drugs.The analysis shows that alteplase has strong thrombolytic effect and few bleeding adverse reactions.It is the main clinically recommended thrombolytic drug for the treatment of acute pulmonary embolism.

关 键 词：肺栓塞 组织型纤溶酶原激活物 阿替普酶 纤维蛋白溶解药 溶栓药 综述 

分 类 号：R563.5[医药卫生—呼吸系统]